PCOS / PMOS · 10 min read · 2026-05-16
PCOS Becomes PMOS: The Lancet Commission Rename, Diagnostic Evolution, and Implications for the Supplement Market
In May 2026, the Lancet Commission on Polycystic Ovary Syndrome — convened after years of advocacy from patient organizations, endocrinologists, and reproductive medicine specialists who argued that the existing name fundamentally misrepresented the condition — voted 87/90 to rename PCOS to PMOS: Polyendocrine-Metabolic-Ovarian Syndrome. This is not a cosmetic rebrand. The name change reflects a paradigm shift in how the condition is understood mechanistically, coded clinically, communicated to patients, and likely to be researched and treated in the decade ahead. PCOS as a name carried two fundamental inaccuracies: "polycystic" — the majority of women meeting PCOS diagnostic criteria by Rotterdam 2003 standards (two of three criteria: oligo-anovulation, clinical/biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound) do not have visible ovarian cysts; they have polyfollicular ovaries with arrested folliculogenesis, a distinct anatomical picture that is diagnostically different from true "cysts." "Ovary" — PCOS is not primarily an ovarian disease; the ovarian changes are downstream manifestations of a systemic polyendocrine and metabolic condition involving insulin resistance, hypothalamic GnRH pulsatility abnormalities, adrenal DHEA-S overproduction, and adipose tissue inflammation. PMOS — Polyendocrine-Metabolic-Ovarian Syndrome — captures the upstream endocrine and metabolic drivers while retaining "Ovarian" to maintain diagnostic recognition and reduce implementation friction.
Why "Polycystic Ovary" Was Always a Misnomer: The Diagnostic Archaeology
[Image: PCOS diagnostic criteria evolution: Stein-Leventhal 1935 → NIH 1990 (anovulation + hyperandrogenism) → Rotterdam 2003 (2 of 3: anovulation/hyperandrogenism/PCOM) → Lancet PMOS 2026; polycystic ovarian morphology specificity chart: 60–70% PCOS without PCOM; 25% normal women with PCOM]
The term "polycystic ovary" originates with Stein and Leventhal's 1935 report of women with amenorrhea, hirsutism, and bilaterally enlarged ovaries with multiple small follicles — conditions relieved by bilateral ovarian wedge resection. The "cysts" were not cysts in the pathological sense (fluid-filled epithelial structures); they were arrested antral follicles (2–9 mm diameter) that failed to progress through dominant follicle selection due to impaired FSH signaling and LH pulse frequency excess. The ovarian morphology criterion in Rotterdam 2003 (≥12 follicles per ovary, 2–9 mm diameter, or ovarian volume >10 mL) was added to the diagnostic framework despite not being a mandatory criterion — the majority of PCOS diagnoses are established by oligo-anovulation plus hyperandrogenism, without any ultrasound requirement. Studies across multiple populations consistently find that 60–70% of women with PCOS by Rotterdam criteria do not show polycystic ovarian morphology on standard ultrasound. Conversely, 25% of normal women show polycystic ovarian morphology without any hormonal abnormality. The polycystic morphology criterion is the least specific and least mechanistically informative of the three Rotterdam criteria — yet it defines the condition's name and creates the most patient confusion ("I was told I have cysts but the doctor said they aren't really cysts"). PMOS eliminates this foundational nomenclature error.
The Lancet Commission Process: 90 Experts, 87 Votes, and the PMOS Framework
[Image: PMOS commission framework: 90 experts, 87/90 vote May 2026; PMOS acronym: Polyendocrine (hypothalamic GnRH excess + LH hypersecretion + adrenal DHEA-S) + Metabolic (insulin resistance pancreatic compensation) + Ovarian (manifestation of upstream endocrine dysfunction); Rotterdam 2003 vs PMOS 2026 criteria schematic]
The Lancet Commission on PCOS was convened in 2024 and included 90 experts across reproductive endocrinology, metabolic medicine, gynecology, patient advocacy, and public health from 27 countries. The commission was charged with evaluating: (1) the clinical and scientific accuracy of the existing name; (2) the patient experience of the name (surveys consistently show PCOS patients find the name confusing, anxiety-provoking, and misleading — many patients report being told they "don't have cysts" after years of living with a name implying they do); (3) ICD coding implications and implementation pathway for a name change; (4) proposed alternative names from a shortlist. The PMOS vote (87/90, with 2 abstentions and 1 dissent) reflects near-consensus that the name change is both scientifically justified and patient-centered. "Polyendocrine" captures the multi-gland dysfunction: hypothalamic GnRH excess pulsatility (from reduced progesterone feedback in anovulatory cycles), pituitary LH hypersecretion, pancreatic beta-cell insulin hypersecretion (compensating for peripheral IR), adrenal zone reticularis DHEA-S overproduction in 50–70% of cases. "Metabolic" captures the central insulin resistance phenotype — the condition's most clinically important feature in terms of cardiovascular and metabolic long-term risk. "Ovarian" retains ovarian identification for clinical continuity. The name is mechanistically accurate; the question is implementation velocity.
ICD-11 Implementation, Reimbursement Coding, and Diagnostic Implications
[Image: ICD-11 implementation timeline: PMOS Lancet Commission May 2026 → WHO technical advisory submission 2026 → ICD-11 coding revision 2027–2028 → national implementation 2027–2030; parallel terminology period schematic; ICD-10 E28.2 → ICD-11 GA34.0 → future PMOS code]
ICD-11 (International Classification of Diseases, 11th revision), adopted by the WHO in 2022 and in progressive national implementation through 2025–2027, uses a different coding structure than ICD-10. PCOS currently codes under ICD-10 E28.2 (polycystic ovarian syndrome) and ICD-11 GA34.0. The PMOS rename will require a WHO ICD-11 revision proposal — a formal process involving member state submissions, technical review, and annual coding updates. The ICD-11 update cycle runs annually; assuming the WHO technical advisory group accepts a PMOS proposal in late 2026 (based on the Lancet Commission publication timing), implementation in ICD-11 code changes could occur in the 2027–2028 coding cycle. In the interim — the period of maximum clinical ambiguity — providers will continue using PCOS/E28.2 for reimbursement while the scientific literature transitions to PMOS nomenclature. Clinicians should expect 3–5 years of parallel terminology in practice. Insurance coverage implications are minimal (the underlying condition criteria are unchanged — only the name transitions), but prior authorization paperwork referencing "PCOS" will need updating. Genetic testing code implications (BRCA-parallel precedent for specialized endocrine coding) are under discussion within the commission's implementation working group.
Supplement Market Repositioning and Clinical Trial Endpoint Evolution
[Image: PMOS supplement market repositioning: metabolic pillar (inositol/berberine insulin sensitization) + polyendocrine pillar (spearmint/saw palmetto androgen modulation) + anti-inflammatory pillar (omega-3/NAC/vitamin D); clinical trial endpoint evolution from PCOM morphology → HOMA-IR / FAI / AMH / patient-reported outcomes]
The PMOS rename has direct commercial and research implications for the supplement market. "PCOS supplements" as a category — currently anchored to products featuring inositol, berberine, spearmint, NAC, and DIM — will face a positioning transition as the condition label changes. For well-positioned supplement brands, this is an opportunity to reframe around PMOS's mechanistic language: insulin sensitization (inositol, berberine — targeting the "metabolic" pillar), androgen modulation (spearmint for anti-androgenic effects, saw palmetto SPE — targeting the "polyendocrine" adrenal and ovarian androgen axis), and anti-inflammatory support (NAC, omega-3 — targeting the adipose inflammation underlying insulin resistance). The "metabolic" framing also opens connections to metabolic syndrome supplement positioning (chromium, magnesium, alpha-lipoic acid) that were less natural under the "polycystic ovary" framing. For clinical trials, the PMOS rename has endpoint implications: the Rotterdam criteria's polycystic ovarian morphology endpoint is likely to be de-emphasized in favor of metabolic endpoints (insulin sensitivity by HOMA-IR, AUC from OGTT, adipokine profiles), hormonal endpoints (free androgen index, LH:FSH ratio, AMH), and patient-reported outcome measures (menstrual regularity, quality of life, fertility). Inositol's position is strengthened by the PMOS metabolic framing: its mechanism (FSH receptor sensitivity and insulin signaling PI3K pathway intersection) is more naturally described as metabolic correction than as "PCOS treatment."
The bottom line
The PCOS → PMOS rename is a rare event in clinical medicine: a condition name change driven not by new disease entity discovery but by the accumulated weight of 90 years of mechanistic understanding demonstrating that the original name was anatomically and physiologically wrong. For investors, the rename signals a clinical-academic consensus on the metabolic-polyendocrine framing that will increasingly shape clinical trial design, reimbursement criteria, and product positioning in the women's health supplement and pharmaceutical market. For clinicians and patients, it offers a name that finally aligns with the biology — reducing the diagnostic confusion that has complicated patient communication since 1935. Selene's PCOS/PMOS content and protocol already reflects the metabolic-insulin-hormonal axis framework that PMOS legitimizes; the rename validates the mechanistic approach that precision hormonal supplementation has been building toward.
Questions
Will the PMOS rename affect diagnostic criteria, or only nomenclature?
The Lancet Commission's 2026 publication proposes nomenclature change within the existing Rotterdam 2003 diagnostic criterion framework — the three Rotterdam criteria (oligo-anovulation, clinical/biochemical hyperandrogenism, polycystic ovarian morphology) remain operative during the transition. However, the commission's implementation document recommends de-emphasizing the polycystic ovarian morphology criterion (given its low specificity and lack of mechanistic centrality) and elevating metabolic markers (insulin resistance, cardiometabolic risk assessment) as mandatory components of the diagnostic workup even when not formally required for diagnosis. The diagnostic workup will likely expand to include HOMA-IR, full lipid panel, and 2-hour OGTT in all PMOS patients — not just those with overt metabolic symptoms — reflecting the metabolic-first framing of the new name.
What does the PMOS rename mean for the PCOS research literature — is all prior PCOS research now reframed?
Prior PCOS research literature remains valid and applicable — the condition criteria are unchanged, and women enrolled in PCOS trials under Rotterdam criteria are the same population that will be diagnosed with PMOS under the new name. The terminology shift creates a bibliometric transition: PubMed searches for "PMOS" will initially return few results while "PCOS" contains decades of literature; cross-referenced searches will be necessary for 10–15 years until the PMOS literature matures. Journals are expected to add "PMOS (formerly PCOS)" as a recommended citation format for transition papers, similar to how condition renaming has been managed in other fields (e.g., "non-alcoholic fatty liver disease → MASLD"). Meta-analyses published after the rename will need to explicitly include both PCOS and PMOS search terms to avoid literature gaps.
How should direct-to-consumer supplement brands position themselves during the PCOS/PMOS transition period?
The strategic recommendation for supplement brands: begin dual-naming ("for PCOS, now also known as PMOS") immediately upon publication of the Lancet Commission formal paper, while building content that educates consumers on the name change and the mechanistic rationale. Brands that have invested in insulin-sensitization and metabolic-axis positioning (inositol, berberine, chromium) are mechanistically aligned with the PMOS "metabolic" pillar and can lean into this positioning aggressively. Brands that have been primarily "ovarian" or "cycle regulation" positioned (vitex, evening primrose) have a weaker natural fit with PMOS's metabolic-polyendocrine framing and may need to reposition toward the ovulatory function restoration narrative within the polyendocrine framework. The 3–5 year parallel naming period is the optimal window for market repositioning without the abruptness of a hard cutover.
Does the PMOS rename affect the inositol mechanism or dosing evidence base?
No — inositol's mechanism (myo-inositol as FSH receptor signal transduction mediator; PCOS follicular fluid MI:DCI ratio dysregulation; insulin signaling PI3K pathway intersection) is strengthened, not weakened, by the PMOS metabolic-polyendocrine framing. The insulin resistance component of PMOS makes inositol's insulin-sensitizing mechanism more central, not more peripheral, to the condition's biological story. The 4 g/day MI + 400 mg/day DCI dosing from the PMID 38163998 meta-analysis is directly applicable. If anything, the PMOS metabolic emphasis may accelerate research interest in inositol's metabolic effects specifically — OGTT outcomes, insulin AUC, HOMA-IR — rather than the ovulation-only outcomes that dominated earlier PCOS-inositol literature.
Build an evidence-based PCOS / PMOS protocol.
Selene's personalization engine maps your hormonal profile to peer-reviewed ingredient stacks, adjusted for your cycle phase and symptom cluster.
View the PCOS / PMOS clinical profile →